Hugh Rosen's most recent trade in Regulus Therapeutics Inc was a trade of 62,500 Common Stock done . Disclosure was reported to the exchange on April 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Hugh Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 62,500 | 64,271 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Hugh Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Hugh Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Hugh Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Hugh Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |